TME PHARM.CONF.IPO EO 1- (0N6A) — Financial Flexibility Index
TME PHARM.CONF.IPO EO 1- (0N6A) has a Financial Flexibility Index of -0.92x as of December 2025. Free cash flow of €-3.42 Million (operating CF €-3.42 Million minus capex €0.00) represents -1% of total liabilities (€3.72 Million). Check TME PHARM.CONF.IPO EO 1- tangible book value ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
TME PHARM.CONF.IPO EO 1- Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for TME PHARM.CONF.IPO EO 1- across 5 annual periods. For the full cash flow conversion analysis, see TME PHARM.CONF.IPO EO 1- cash conversion from operations.
Annual Financial Flexibility Index for TME PHARM.CONF.IPO EO 1- (2021–2025)
Year-by-year free cash flow to debt coverage for TME PHARM.CONF.IPO EO 1-. Explore TME PHARM.CONF.IPO EO 1- cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €-3.42 Million | €3.72 Million | ▲ +64.3% |
| 2024 | -2.58x | €-4.62 Million | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.62 Million | €-5.63 Million | €2.79 Million | ▼ -8.3% |
| 2022 | -1.86x | €-12.12 Million | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.37 Million | €-12.38 Million | €5.27 Million | — |